Safety and Efficacy: The Role of Chemistry, Manufacturing, and Controls in Pharmaceutical Drug Development

References

• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline, Maintenance of the ICH Guideline on Non‐Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals, M3 (M), Step 4 of the ICH Process. 9 November, 2000, http://www.ich.org/MediaServer.jser?@_ID=506&@_MODE=GLB (accessed July 2003)
   Google Scholar
• Kuhlmann J. Drug research: from the idea to the product. Int. J. Clin. Pharmacol. Ther. 1997; 35(12)541–552
   PubMed Web of Science ®Google Scholar
• Lesko L. J., Rowland M., Peck C. C., Blaschke T. F. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm. Res. 2000; 17(11)1335–1344
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation of Technical Requirements For Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline, Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies, S3A, Step 4 of the ICH Process. 27 October, 1994, http://www.ich.org/MediaServer.jser?@_ID=495&@_MODE=GLB (accessed October 2003)
   Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Frequently Asked Questions on Drug Development and Investigational New Drug Applications. October 16, 2001, http://www.fda.gov/cder/about/smallbiz/faq.htm (accessed July 2003)
   Google Scholar
• Aarons L., Karlsson M. O., Mentre F., Rombout F., Steimer J.‐L., van Peer A. Role of modeling and simulation in Phase I drug development. Eur. J. Pharm. Sci. 2001; 13(2)115–122, [CSA]
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration. April 1, 2003, 21 CFR Part 312.34, http://www.access.gpo.gov/nara/cfr/waisidx_03/21cfr312_03.html (accessed July 2003)
   Google Scholar
• Meibohm B., Derendorf H. Pharmacokinetic/pharmacodynamic studies in drug product development. J. Pharm. Sci. 2002; 91(1)18–31
   PubMed Web of Science ®Google Scholar
• Mathot R., Geus W. Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance. Clin. Pharmacol. Ther. 1999; 66(2)140–151, [CSA]
   PubMed Web of Science ®Google Scholar
• Lietman P. S., Laskin O. L. Clinical drug development: human pharmacology, safety, and tolerance trials. Antiviral Agents and Human Viral Disease4th Ed., G. J. Galasso, R. J. Whitley, T. C. Merigan. Lippincott‐Raven, Philadelphia 1997; 113–127
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline, General Considerations for Clinical Trials, E8, Step 4 of the ICH Process. July 17, 1997, http://www.ich.org/MediaServer.jser?@_ID=484&@_MODE=GLB (accessed July 2003)
   Google Scholar
• Edwards L. D. Clinical Trials. Internet Presentation, www.temple.edu/pharmacy_QARA/edwards_Class3a.ppt (accessed July 2003)
   Google Scholar
• Skyler J., Cefalu W., Kourides I., Landschulz W., Balagtas C., Cheng S.‐L., Gelfand R. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomized proof‐of‐concept study. Lancet 2001; 357(9523)331–335
   PubMedGoogle Scholar
• Aurecchia S., Orloff D., Sobel S. Regulatory concerns at various phases of drug development. Am. J. Cardiol. 1998; 81(8A)2F–4F, [CSA]
   Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration. 21 CFR Part 312.21, April 1, 2003, http://www.access.gpo.gov/nara/cfr/waisidx_03/21cfr312_03.html (accessed July 2003)
   Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry, Clinical Studies Section of Labeling for Prescription Drugs and Biologics—Content and Format, Draft Guidance. May, 2001, http://www.fda.gov/cder/guidance/1890dft.pdf (accessed October 2003)
   Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry, Content and Format of the Adverse Reactions Section of Labeling for Human Prescription Drugs and Biologics, Draft Guidance. May, 2000, http://www.fda.gov/cder/guidance/1888dft.pdf (accessed October 2003)
   Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry, IND Meetings for Human Drugs and Biologics, Chemistry, Manufacturing and Controls Information. May, 2001, http://www.fda.gov/cder/guidance/3683fnl.pdf (Accessed July 2003)
   Google Scholar
• Lim C.‐K., Lord G. Current developments in LC‐MS for pharmaceutical analysis. Biol. Pharm. Bull. 2002; 25(5)547–557, [CSA]
   PubMed Web of Science ®Google Scholar
• Jamali F., Mehvar R., Pasutto F. M. Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J. Pharm. Sci. 1989; 78(9)695–715
   PubMed Web of Science ®Google Scholar
• Desta Z., Soukhova N., Morocho A. M., Flockhart D. A. Stereoselective metabolism of cisapride and enantiomer‐enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A. J. Pharmacol. Exp. Ther. 2001; 298(2)508–520, [CSA]
   PubMed Web of Science ®Google Scholar
• VanEikeren P. Commercial manufacture of chiral pharmaceuticals. Chiral Separations: Applications and Technology, S. Ahuja. American Chemical Society, Washington, DC 1997; 9–35
   Google Scholar
• Baker G. B., Prior T. I. Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs. Trends Mol. Med. 2002; 34(7)537–543
   Google Scholar
• Martinez M. N., Amidon G. L. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J. Clin. Pharmacol. 2002; 42(6)620–643, [CSA]
   PubMed Web of Science ®Google Scholar
• Mayer P. R. Absorption, metabolism, and other factors that influence drug exposure in toxicology studies. Toxicol. Pathol. 1995; 23(2)165–169, [CSA]
   PubMed Web of Science ®Google Scholar
• Bundgaard H. Acid‐catalyzed hydrolysis of fosfomycin and its implication in oral absorption of the drug. Int. J. Pharm. 1980; 6(1)1–9
   Google Scholar
• Ali A. A., Farouk A. Comparative studies on the bioavailability of ampicillin anhydrate and trihydrate. Int. J. Pharm. 1981; 9(3)239–243
   Google Scholar
• Garsheva G. B., Vasiliev V. K., Grakovskaya L. K. Bioavailability of ampicillin suspensions. Anitbiotiki 1979; 24(8)609–611
   PubMedGoogle Scholar
• Stephenson G. A., Forbes R. A., Reutzel‐Edens S. M. Characterization of the solid state: quantitative issues. Adv. Drug Deliv. Rev. 2001; 48: 67–90, [CSA]
   PubMed Web of Science ®Google Scholar
• Kobayashi Y., Ito S., Itai S., Yamamoto K. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int. J. Pharm. 2000; 193(2)137–146
   PubMed Web of Science ®Google Scholar
• Bartolomei M., Bertocchi P., Ramusino M. C., Santucci N., Valvo L. Physico‐chemical characterisation of the modifications of I and II of (R,S) propranolol hydrochloride: solubility and dissolution studies. J. Pharm. Biomed. Anal. 1999; 21: 299–309, [CSA]
   PubMed Web of Science ®Google Scholar
• Jahansouz H., Thompson K. C., Brenner G. S., Kaufman M. Investigation of the polymorphism of the angiotensin II antagonist agent MK‐996. Pharm. Dev. Technol. 1999; 4(2)181–187, [CSA]
   PubMed Web of Science ®Google Scholar
• Yakou S., Yamazaki S., Sonobe T., Sugihara M., Fukumuro K., Nagai T. Particle size distribution affects the human bioavailability of phenytoin. Chem. Pharm. Bull. 1986; 34(10)4400–4402
   PubMed Web of Science ®Google Scholar
• Posti J., Katila K., Kostiainen T. Dissolution rate limited bioavailability of flutamide, and in vitro–in vivo correlation. Eur. J. Pharm. Biopharm. 2000; 49(1)35–39, [CSA]
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate—Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, Rockville, MD. August, 2000, http://www.fda.gov/cder/guidance/3618fnl.pdf (accessed May 2003)
   Google Scholar
• Lobenberg R., Amidon G. L. Modern bioavailability, bioequivalence, and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 2000; 50(1)3–12, [CSA]
   PubMed Web of Science ®Google Scholar
• Hoelgaard A., Moller N. Hydrate formation of metronidazole benzoate in aqueous suspensions. Int. J. Pharm. 1983; 15: 213–221
   Web of Science ®Google Scholar
• International Conference on Harmonisation of Technical Requirements For Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline, Q3A(R), Impurities in New Drug Substances, Step 4 of the ICH Process. 7 February, 2002, http://www.ich.org/MediaServer.jser?@_ID=422&@_MODE=GLB (accessed July 2003)
   Google Scholar
• McCrossen S. D., Bryant D. K., Cook B. R., Richards J. J. Comparison of LC detection methods in the investigation of non‐UV detectable organic impurities in a drug substance. J. Pharm. Biomed. Anal. 1998; 17: 455–471, [CSA]
   PubMed Web of Science ®Google Scholar
• Hilhorst M. J., Somsen G. W., de Jong G. J. Capillary electrokinetic separation techniques for profiling of drugs and related products. Electrophoresis 2001; 22: 2542–2564, [CSA]
   PubMed Web of Science ®Google Scholar
• Pifferi G., Mannucci A. Drug impurities: problems and regulations. Boll. Chim. Farm. 1999; 138(10)500–507, [CSA]
   PubMedGoogle Scholar
• Sigvardson K. W., Adams S. P., Barnes T. B., Blom K. F., Fortunak J. M., Haas M. J., Reilly K. L., Repta A. J., Nemeth G. A. The isolation and identification of a toxic impurity in XP315 drug substance. J. Pharm. Biomed. Anal. 2002; 27: 327–334, [CSA]
   PubMed Web of Science ®Google Scholar
• Ermer J., Vogel M. Applications of hyphenated LC‐MS techniques in pharmaceutical analysis. Biomed. Chromatogr. 2000; 14: 373–383, [CSA]
   PubMed Web of Science ®Google Scholar
• Dienemann E., Osifchin R. The role of chemical engineering in process development and optimization. Curr. Opin. Drug Discov. Dev. 2000; 3(6)690–698
   PubMedGoogle Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, Q6A, Step 4 of the ICH Process. 6 October, 1999, http://www.ich.org/MediaServer.jser?@_ID=430&@_MODE=GLB (accessed July 2003)
   Google Scholar
• Ginsburg E. J., Stephens D. A., West P. R., Buko A. M., Robinson D. H., Li L. C., Bommireddi A. R. Identification of a yellow impurity in aged samples of aqueous butamben suspension: evidence for the oxidative degradation of poly(ethylene glycol). J. Pharm. Sci. 2000; 89(6)766–770
   PubMed Web of Science ®Google Scholar
• Stemm N. L., Skoug J. W., Robins R. H. Gradient high performance liquid chromatographic assay for degradation products of adinazolam mesylate in a sustained release tablet formulation. Pharm. Res. 1995; 12(5)738–745
   PubMed Web of Science ®Google Scholar
• Lee S. H., Shin J., Choi J. M., Lee E. Y., Kim D. H., Suh J.‐W., Chang J. H. The impurities of capreomycin make a difference in the safety and pharmacokinetic profiles. Int. J. Antimicrob. Agents 2003; 22: 81–83, [CSA]
   PubMed Web of Science ®Google Scholar
• Bernd R., Gulden B. Chromatography in pharmaceutical analysis: uncertainty versus specifications. Pharm. Technol. Eur. 1997; 9(6)36–44
   Google Scholar
• Wong Y. L. Adverse effects of pharmaceutical excipients in drug therapy. Ann. Acad. Med. Singap. 1993; 22(1)99–102
   PubMedGoogle Scholar
• Eckoff C., Bailey J. R., Collins M. D., Slikker W., Nau H. Influence of dose and pharmaceutical formulation of vitamin A on plasma levels of retinyl esters and retinol and metabolic generation of retinoic acid compounds and β‐glucuronides in the cynomolgus monkey. Toxicol. Appl. Pharmacol. 1991; 111: 116–127, [CSA]
   PubMed Web of Science ®Google Scholar
• Brock M. H., Dansereau R. J., Patel V. S. Use of in vitro and in vivo data in the design, development, and quality control of sustained‐release decongestant dosage forms. Pharmacotherapy 1994; 14(4)430–437, [CSA]
   PubMed Web of Science ®Google Scholar
• Dubost D. C., Kaufman M. J., Zimmerman J. A., Bogusky M. J., Coddington A. B., Pitzenberger S. M. Characterization of a solid state reaction product from a lyophilized formulation of a cyclic heptapeptide. A novel example of an excipient—induced oxidation. Pharm. Res. 1996; 13(12)1811–1814
   PubMed Web of Science ®Google Scholar
• Chowhan Z. T. A rational approach to setting limit tests and standards on impurities in excipients. Pharm. Technol. 1995; 19(8)43–44; 46–48
   Google Scholar
• De Jong H. J. The safety of pharmaceutical excipients. Therapie 1999; 54: 11–14
   PubMed Web of Science ®Google Scholar
• Strattan C. E. 2‐Hydroxypropyl β‐cyclodextrin, Part II: safety and manufacturing issues. Pharm. Technol. 1992; 16(2), pp. 52, 54, 56, 58
   Google Scholar
• Luengo J., Aranguiz T., Sepulveda J., Hernandez L., Von Plessing C. Preliminary pharmacokinetic study of different preparations of acyclovir with β‐cyclodextrin. J. Pharm. Sci. 2002; 91(12)2593–2598
   PubMed Web of Science ®Google Scholar
• Bakshi M., Singh S. Development of validated stability‐indicating assay methods—critical review. J. Pharm. Biomed. Anal. 2002; 28: 1011–1040, [CSA]
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare Products Regulatory Agency. Medicines Act 1968. Guidance Notes on Applications for Clinical Trials Exemptions and Clinical Trials Certificates. May, 2001, Revised. http://www.mca.gov.uk/ (accessed August 2003)
   Google Scholar